UK markets open in 3 hours 21 minutes
  • NIKKEI 225

    27,149.76
    -161.54 (-0.59%)
     
  • HANG SENG

    17,830.96
    -181.19 (-1.01%)
     
  • CRUDE OIL

    88.38
    -0.07 (-0.08%)
     
  • GOLD FUTURES

    1,718.90
    -1.90 (-0.11%)
     
  • DOW

    29,926.94
    -346.93 (-1.15%)
     
  • BTC-GBP

    17,910.56
    -385.64 (-2.11%)
     
  • CMC Crypto 200

    455.00
    -8.13 (-1.76%)
     
  • ^IXIC

    11,073.31
    -75.33 (-0.68%)
     
  • ^FTAS

    3,826.39
    -22.28 (-0.58%)
     

Cannovum AG: Record sales and new customers in the first half of 2022

·2-min read

DGAP-News: Cannovum AG / Key word(s): Half Year Results/Development of Sales
Cannovum AG: Record sales and new customers in the first half of 2022
07.09.2022 / 08:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21), one of the market leaders in the medical cannabis industry, significantly increased both sales and customers in its medical cannabis business in H1 2022. Cannovum AG continues to make progress towards opening the market for over-the-counter cannabis in Germany.

 

Cannovum achieved revenues of 516952 Euros in its operating business (1 HY 2022), an increase of 1231 percent compared to the same period in the previous year (38829 euros). Pia Marten, CEO Cannovum AG: “Our strategy to win the trust of physicians and pharmacists with premium products exceeded our expectations. We are well within our plans in terms of sales growth and new customer acquisition.”

 

Cannovum only sells products that meet the highest pharmaceutical standards.  "We continue to make an important contribution to supplying the German market with high-quality cannabis," says Marten.

 

This strong commitment to quality is well received. Already more than 300 and thus more than every 10th pharmacy supplying cannabis is a regular customer of Cannovum.

 

Cannovum's success is also attributed to its professional and experienced sales force, which supports doctors and local pharmacies. In light of the upcoming legalization of cannabis, a focus will be on the cooperation with pharmacies as an essential distribution channel.

 

For more information about Cannovum AG and Cannovum Health eG, in which the operating business with medical cannabis of Cannovum AG is consolidated, please visit: https://cannovum.de/investor-relations

Contact:

Klaus Madzia, IR & PR, Cannovum AG

Phone +49 30 3982 163 62, klaus.madzia@cannovum.com

 

 

Cannovum AG is the first publicly listed German fully licensed medical cannabis company. The shares are traded on the stock exchanges in Düsseldorf, Munich, Berlin, Hamburg and gettex. Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for simplified and equitable access to cannabis-based therapies.

For more information, visit www.cannovum.de

 

 

 

 


07.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Cannovum AG

Rheinsberger Str. 76/77

10115 Berlin

Germany

Phone:

+49 (0)30 3982 16360

E-mail:

ir@cannovum.com

Internet:

www.cannovum.com

ISIN:

DE000A2LQU21

WKN:

A2LQU2

Listed:

Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich

EQS News ID:

1436751


 

End of News

DGAP News Service

show this
show this